Ocular Immunology and Inflammation · 2016 · 32 citations · 29 references
MedicineImmunologyOphthalmologyDiabetologyInflammationOcular ImmunologyDiabetic RetinopathyImmunopathology Of The EyeMacular DiseaseOcular Cytokine BiologyOcular InflammationRetinal ImmunologyControl Group DesignCytokine Signaling At The Blood-retinal BarrierDiabetic Retinopathy CytokinesDiabetic Retinopathy ImmunologyMatched Control GroupNon-proliferative Diabetic RetinopathyNonproliferative Diabetic Retinopathy
PURPOSE: To examine the role of interleukin 27(IL-27) and interleukin 35 (IL-35) in diabetic retinopathy (DR). METHODS: Patients with diabetes mellitus were divided into three groups: diabetes without retinopathy (DWR), non-proliferative diabetic retinopathy (NPDR), and proliferative diabetic retinopathy (PDR). Patients with idiopathic macular epiretinal membrane (IMEM) were included as a control group. The serum and vitreous levels of IL-27 and IL-35 were measured using ELISA. RESULTS: The serum levels of IL-27 (median 240.900 pg/mL, range 42.224 - 617.810 pg/mL; p < 0.001) and IL-35 (median 11.875 ng/mL, range 8.640 - 19.340 ng/mL; p < 0.001) were significantly decreased in PDR patients compared to controls (median 2712.310 pg/mL, range 1005.375-5786.877 pg/mL and median 25.185 ng/mL, range 22.845 - 29.590 ng/mL, respectively). The vitreous levels of IL-35 were significantly decreased in PDR patients (16.32 ± 3.24 ng/mL) compared to controls (24.54 ± 5.86 ng/mL, p < 0.001). CONCLUSIONS: Serum and vitreous levels of IL-35 and serum level of IL-27 may be associated with the pathogenesis of PDR.
29